DNA fingerprinting of the NCI-60 cell line panel

The National Cancer Institute's NCI-60 cell line panel, the most extensively characterized set of cells in existence and a public resource, is frequently used as a screening tool for drug discovery. Because many laboratories around the world rely on data from the NCI-60 cells, confirmation of their genetic identities represents an essential step in validating results from them. Given the consequences of cell line contamination or misidentification, quality control measures should routinely include DNA fingerprinting. We have, therefore, used standard DNA microsatellite short tandem repeats to profile the NCI-60, and the resulting DNA fingerprints are provided here as a reference. Consistent with previous reports, the fingerprints suggest that several NCI-60 lines have common origins: the melanoma lines MDA-MB-435, MDA-N, and M14; the central nervous system lines U251 and SNB-19; the ovarian lines OVCAR-8 and OVCAR-8/ADR (also called NCI/ADR); and the prostate lines DU-145, DU-145 (ATCC), and RC0.1. Those lines also show that the ability to connect two fingerprints to the same origin is not affected by stable transfection or by the development of multidrug resistance. As expected, DNA fingerprints were not able to distinguish different tissues-of-origin. The fingerprints serve principally as a barcodes.[Mol Cancer Ther 2009;8(4):713–24]

[1]  Gabriel S. Eichler,et al.  Asparagine synthetase as a causal, predictive biomarker for l-asparaginase activity in ovarian cancer cells , 2006, Molecular Cancer Therapeutics.

[2]  Christian A. Rees,et al.  Systematic variation in gene expression patterns in human cancer cell lines , 2000, Nature Genetics.

[3]  J. Weinstein,et al.  In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation , 2008, Molecular Cancer Therapeutics.

[4]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[5]  Y. Pommier,et al.  Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. , 2001, Cancer research.

[6]  J. Butler,et al.  Genetics and Genomics of Core Short Tandem Repeat Loci Used in Human Identity Testing , 2006, Journal of forensic sciences.

[7]  Domenico Coppola,et al.  Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer , 2000, Oncogene.

[8]  John N Weinstein,et al.  MicroRNA expression profiles for the NCI-60 cancer cell panel , 2007, Molecular Cancer Therapeutics.

[9]  A. Jeffreys,et al.  Individual-specific ‘fingerprints’ of human DNA , 1985, Nature.

[10]  Chris Tyler-Smith,et al.  Reliability of DNA-based sex tests , 1998, Nature Genetics.

[11]  J. Masters.  Re: false cell lines. , 2002, Experimental cell research.

[12]  W. Nelson-Rees,et al.  HeLa-like marker chromosomes and type-A variant glucose-6-phosphate dehydrogenase isoenzyme in human cell cultures producing Mason-Pfizer monkey virus-like particles. , 1974, Journal of the National Cancer Institute.

[13]  S. Holbeck,et al.  Update on NCI in vitro drug screen utilities. , 2004, European journal of cancer.

[14]  M. Boyd,et al.  Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen , 1995 .

[15]  W. Nelson-Rees,et al.  Banded Marker Chromosomes as Indicators of Intraspecies Cellular Contamination , 1974, Science.

[16]  J A Thomson,et al.  Short tandem repeat profiling provides an international reference standard for human cell lines , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  H. Drexler,et al.  Widespread intraspecies cross‐contamination of human tumor cell lines arising at source , 1999, International journal of cancer.

[18]  John N Weinstein,et al.  Integromic analysis of the NCI-60 cancer cell lines. , 2004, Breast disease.

[19]  John N. Weinstein,et al.  Spotlight on molecular profiling: “Integromic” analysis of the NCI-60 cancer cell lines , 2006, Molecular Cancer Therapeutics.

[20]  M. Boyd,et al.  Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. , 1992, Anticancer research.

[21]  R. Wichelhausen,et al.  Contamination of human cell cultures by pleuropneumonialike organisms. , 1956, Science.

[22]  Jae K. Lee,et al.  Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study , 2007, Molecular Cancer Therapeutics.

[23]  R. Shoemaker.  The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.

[24]  J. Weinstein,et al.  Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers , 2008, Molecular Cancer Therapeutics.

[25]  A. Feinberg,et al.  Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells , 2007, Molecular Cancer Therapeutics.

[26]  J. Weinstein,et al.  Karyotypic complexity of the NCI-60 drug-screening panel. , 2003, Cancer research.

[27]  William C Reinhold,et al.  MicroRNAs modulate the chemosensitivity of tumor cells , 2008, Molecular Cancer Therapeutics.

[28]  J. Weinstein,et al.  Asparagine synthetase is a predictive biomarker of l-asparaginase activity in ovarian cancer cell lines , 2008, Molecular Cancer Therapeutics.

[29]  Richard Lugg,et al.  Mutation analysis of 24 known cancer genes in the NCI-60 cell line set , 2006, Molecular Cancer Therapeutics.

[30]  William C Reinhold,et al.  Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel , 2006, Molecular Cancer Therapeutics.

[31]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[32]  C. Kimpton,et al.  A highly discriminating octoplex short tandem repeat polymerase chain reaction system suitable for human individual identification , 1995, Electrophoresis.